Frankfurt - Delayed Quote EUR
Collegium Pharmaceutical, Inc. (354.F)
25.00
-0.80
(-3.10%)
At close: May 23 at 3:57:39 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 182.26M | 189.13M | 744.27M | 772.67M |
| Low Estimate | 181.98M | 187.8M | 740.5M | 747.3M |
| High Estimate | 182.4M | 191.5M | 749.2M | 800.8M |
| Year Ago Sales | 145.28M | 159.3M | 631.45M | 744.27M |
| Sales Growth (year/est) | 25.46% | 18.73% | 17.87% | 3.82% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 354.F | -- | -- | -- | -- |
| S&P 500 | 12.65% | 2.47% | 7.33% | 14.11% |
Upgrades & Downgrades
| Reiterates | Piper Sandler: Neutral to Neutral | 5/9/2025 |
| Reiterates | Needham: Buy to Buy | 4/9/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/24/2025 |
| Maintains | Piper Sandler: Neutral to Neutral | 2/4/2025 |
| Upgrade | Needham: Hold to Buy | 1/10/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/10/2025 |